Carl leads DeciBio’s advanced therapies practice. He brings experience across biopharma, manufacturing/bioprocessing, and supply chain considerations for his clients. He has executed on projects ranging from pipeline prioritization/life cycle management, indication road mapping, growth strategy, and M&A projects across healthcare, life science tools, and pharma (cell and gene therapies). Carl holds a B.S. from the university of California, Berkeley, and a Ph.D. from MIT where he trained with Professor Robert Langer.